Top Markets
#1 Black Phoenix Black Phoenix +354.71%
#2 Glidr Glidr +84.34%
#3 OpenEden OpenEden +71.47%
#4 Gold Park Gold Park +68.86%
#5 Akedo Akedo +55.26%
#6 BasedHype BasedHype +26.68%
#7 Cryptopia Cryptopia +21.54%
#8 Humanity Humanity +20.22%
#9 Avantis Avantis +19.35%
#10 Ether.fi Ether.fi +17.32%
Coin of the day
Black Phoenix Black Phoenix
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Synairgen plc Synairgen plc

Synairgen plc

SNG
Classement en actions #40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
Prix de l'action
$0.01292666
Dernière synchronisation: 2025-04-08
Capitalisation boursière
$157.54K
Changement (1 jour)
6.84%
Changement (1 an)
0.00%
Pays
GB
Échange Synairgen plc (SNG)

Catégorie

Healthcare
Revenus pour Synairgen plc (SNG)
Revenus en Jun 2024 TTM : 0.00
Selon les derniers rapports financiers de Synairgen plc, le chiffre d'affaires actuel de l'entreprise (TTM) est de 0.00. En 2022, l'entreprise a réalisé un chiffre d'affaires de 0.00 égal à le chiffre d'affaires de l'année 2021, qui était de 0.00. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Synairgen plc de 2004 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
2026 (TTM) 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 -100.00%
2018 $133.74 -98.03%
2017 $6.79K 0.00%
2016 0.00 -100.00%
2015 $36.84 -99.45%
2014 $6.68K 0.00%
2013 0.00 0.00%
2012 0.00 -100.00%
2011 $248.65K 0.00%
2010 0.00 0.00%
2009 0.00 0.00%
2008 0.00 -100.00%
2007 $156.44K 3.46%
2006 $151.21K -58.23%
2005 $361.99K 143.32%
2004 $148.77K 0.00%
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE